Country websites:

Outlook

We continue to shape the future of the dialysis industry.

We continue to shape the future of the dialysis industry.

1 Outlook 2018: excluding the effects from the acquisition of NxStage Medical, Inc. and Sound Physicians divestment.
2 Results 2017: adjusted for impacts from IFRS 15 implementation of €486 M.
3 Key performance indicator used for internal management.
4 Excluding the 2018 Sound Valuation Impact.
5 Net income attributable to shareholders of FMC AG & Co. KGaA.
6 Excluding the 2017 impacts from the VA Agreement, Natural Disaster Costs, FCPA related charge, as well as the impacts from the U.S. Tax Reform.
7 Full-time equivalents.

Vision 2020

Number of dialysis patients worldwide - forecast to 2025

Number of dialysis patients worldwide – forecast to 2025
1 Internal estimates

At the end of 2017, around 3.2 million patients received dialysis. According to estimates, the number of people worldwide suffering from chronic kidney failure and requiring dialysis treatment is rising at a relatively constant rate of around 6 % annually. It is expected to reach more than 3.4 million patients in 2018 and approximately 4.9 million by 2025. Social trends contribute to this rise in patient numbers. In Europe and the U.S. in particular, they include the aging population and the increasing incidence of diabetes and hypertension, two illnesses that frequently precede the onset of end-stage renal disease. In developing and emerging countries, the growing population and gradually improved access to dialysis as a result fo increasing wealth are key factors that further boost demand for dialysis products and services. We want to continue to make a significant contribution to meeting this demand in the future.


Revenue growth until 2020

Based on our strategic core competencies, we set ourselves long-term targets in 2014 with our growth strategy 2020 ( Vision 2020 ):

  • Accelerate revenue growth: The aim is to increase Fresenius Medical Care’s revenue to € 24 BN by 2020 based upon exchange rates prevailing at the beginning of 2017, excluding effects from the NxStage acquisition, (gain) loss related to divestitures of Care Coordination activities and excluding the effect from IFRS 15 implementation, corresponding to an average annual growth rate of around 10%. This increase in revenue should stem from both organic growth and acquisitions.
  • Deliver sustainable and profitable growth: We expect high single-digit annual growth in net income based upon exchange rates prevailing at the beginning of 2017 and excluding the effects from the NxStage acquisition, the Sound Physicians divestment and recurring impacts from the U.S. Tax Reform. In 2017, we also announced the second phase of our Global Efficiency Program (GEP II). Starting in 2018, GEP II targets to achieve sustained cost improvements of € 100 M to € 200 M per annum by 2020.
Contact us for further information

Related content